TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17253134
Drug: mesalazine 1.6
Normalized name: Mesalazine 1.6 g gastro-resistant and prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalazine 1.6 g/d 10 days per month (group B)
Study: 10965287
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment (Cognitive Therapy or Phenelzine)
Study: 10965287
Drug: Discontinued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued treatment (Pill placebo)
Study: 8641739
Drug: Losartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (angiotensin II receptor antagonist)
Study: 18830043
Drug: Calcitonin (nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (nasal spray preparations)
Study: 10084441
Drug: Low-dosage pulsed
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage pulsed ultrasound (mean dosage 172.8 J)
Study: 10084441
Drug: High-dosage pulsed
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage pulsed ultrasound (mean dosage 345.6 J)
Study: 7597425
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 and doxorubicin 75 mg/m2 every 3 weeks
Study: 7597425
Drug: Doxorubicin 50
Normalized name: DOXOrubicin 50 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m2 followed by paclitaxel 150 mg/m2
Study: 7597425
Drug: Doxorubicin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin as an intravenous push and paclitaxel as a 24-hour continuous infusion
Study: 1975200
Drug: mequitazine 5
Normalized name: mequitazine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mequitazine 5 mg bd
Study: 1975200
Drug: terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 60 mg bd
Study: 24022431
Drug: Initial antibiotic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antibiotic treatment followed by delayed laparoscopic cholecystectomy at days 7 to 45 (group DLC)
Study: 16891381
Drug: Irbesartan (228±93
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (228±93 mg/day) for at least 2 weeks prior to cardioversion
Study: 12673783
Drug: Glimepiride +
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride + NPH insulin at bedtime
Study: 12673783
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin twice daily
Study: 12673783
Drug: 30/70 mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30/70 mixture of short-acting and NPH insulin twice daily
Study: 6141727
Drug: Nadolol in
Normalized name: Product containing nadolol in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol in combination with isosorbide dinitrate and nifedipine
Study: 6141727
Drug: Nadolol and
Normalized name: nadolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol and large doses of nifedipine
Study: 6141727
Drug: Nadolol alone
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol alone and in combination with isosorbide dinitrate
Study: 6141727
Drug: All drug
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drug combinations
Study: 25536449
Drug: Management strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management strategies including screening and treatment of subclinical hypothyroidism
Study: 23731684
Drug: PEEP titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEEP titration with the four strategies
Study: 20521648
Drug: Recombinant NDV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant NDV expressing H9 AIV hemagglutinin (HA), administered as a single dose of 10^6 50% egg infectious dose intranasally.
Study: 12964321
Drug: 12-hour treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-hour treatment with self-adhesive hydroactive polyurethane dressing (Cutinova thin)
Study: 12964321
Drug: 24-hour treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour treatment with self-adhesive hydroactive polyurethane dressing (Cutinova thin)
Study: 9461709
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with advanced renal insufficiency (serum creatinine levels above 265.3 mumol/l)
Study: 9461709
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with mild renal failure (serum creatinine levels below 265.3 mumol/l)
Study: 7948237
Drug: Intraperitoneal vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal vancomycin plus oral rifampin
Study: 7948237
Drug: Oral trimethoprim/sulfamethoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral trimethoprim/sulfamethoxazole (TMP/SMX)
Study: 19488999
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus 1-alpha-hydroxyvitamin D3 (1-alpha(OH)D3; 0.5 microg per day)
Study: 16688412
Drug: Almotriptan (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan (6.25 to 12.5 mg)
Study: 15305946
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three drugs (Triamcinolone, Montelukast, Nedocromil)
Study: 8217174
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose and lactated Ringer's solution
Study: 8217174
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusions
Study: 31577797
Drug: Group antenatal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group antenatal care (G-ANC)
Study: 31368121
Drug: Single implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single implant mandibular overdenture (SIO)
Study: 24827469
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (twice weekly for 6 weeks)
Study: 16003267
Drug: Preload reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preload reduction with Valsalva maneuver (nonstandardized and standardized) and sublingual nitroglycerin
Study: 12033698
Drug: Twelve-Step Facilitation
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twelve-Step Facilitation (TSF) therapy
Study: 12033698
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) and Motivational Enhancement Therapy (MET)
Study: 7564453
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (10 gm intravenously over 20 minutes before sternotomy and a placebo infusion over 5 hours)
Study: 7564453
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (10 gm intravenously over 20 minutes and another 10 gm infused over 5 hours)
Study: 7564453
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% normal saline solution bolus and infusion over 5 hours)
Study: 7564453
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (10 gm)
Study: 7564453
Drug: Continued tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued tranexamic acid infusion (10 gm over 5 hours)
Study: 2075481
Drug: Clindamycin 300
Normalized name: clindamycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 300 mg (regimen A)
Study: 2075481
Drug: Clindamycin 600
Normalized name: clindamycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 600 mg (regimen B)
Study: 6992823
Drug: Labetalol (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (400-800 mg daily)
Study: 6992823
Drug: Labetalol (1200-1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (1200-1600 mg daily)
Study: 6992823
Drug: Acebutolol (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400-800 mg daily)
Study: 27662018
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (4 cycles of standard anthracycline-based chemotherapy)
Study: 27662018
Drug: No induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No induction chemotherapy
Study: 27662018
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (per protocol)
Study: 27662018
Drug: No induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: No induction chemotherapy (per protocol)
Study: 27662018
Drug: MEL140 (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEL140 (high-dose melphalan)
Study: 27662018
Drug: Mobilization chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilization chemotherapy and tandem MEL140
Study: 22248762
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL to 0.5% ropivacaine
Study: 22248762
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL to 0.5% ropivacaine
Study: 22248762
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL to 1% ropivacaine
Study: 17118993
Drug: Counterregulatory hormones
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Counterregulatory hormones during exercise
Study: 11916896
Drug: Daily micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily micronutrient enriched foods (25‐100% recommended daily amount)
Study: 9859596
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available tablet (control)
Study: 7889183
Drug: Oral TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TRH (40 mg, 12 hourly) plus metoclopramide (10 mg, 8 hourly)
Study: 7889183
Drug: Oral TRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TRH (40 mg, 12 hourly) plus placebo (one capsule, 8 hourly)
Study: 27574260
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.375% ropivacaine plus tramadol 50 mg
Study: 27574260
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.375% ropivacaine plus tramadol 100 mg
Study: 22949150
Drug: Gemcitabine (1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,250 mg/m² days 1 and 8 of a 3-week cycle)
Study: 22949150
Drug: Second-line pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line pemetrexed (500 mg/m² once every 21 days)
Study: 17604912
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg cortisol (oral administration)
Study: 16100331
Drug: Culturally competent
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally competent dietary self‐management intervention consisting of 4 weekly classes in low‐fat dietary strategies, 5 monthly peer‐professional group discussions, and weekly telephone follow‐up
Study: 12859585
Drug: Oral eletriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral eletriptan 40 mg
Study: 15679698
Drug: Oral eletriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral eletriptan 80 mg
Study: 10370679
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g Ceftriaxone
Study: 10370679
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g Ceftriaxone
Study: 10370679
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g or 2 g)
Study: 8958612
Drug: Warfarin (Coumadin)
Normalized name: WARFARIN (COUMADIN) NA 1MG TAB
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (Coumadin) therapy with guidelines for initiation, monitoring, and reversal
Study: 1515384
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml physiologic saline
Study: 1515384
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml (1 mg) 0.5% phenylephrine plus 0.8 ml normal saline
Study: 1515384
Drug: 0.4 ml
Normalized name: ethanol 0.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 ml phenylephrine plus 0.6 ml normal saline
Study: 1515384
Drug: 0.6 ml
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 ml phenylephrine plus 0.4 ml normal saline
Study: 1515384
Drug: 0.8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 ml phenylephrine plus 0.2 ml normal saline
Study: 6093522
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g daily
Study: 6093522
Drug: Cefazolin 3
Normalized name: cefazolin 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 3 to 4 g daily
Study: 30449536
Drug: Intramuscular dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular dexamethasone at 10 mg
Study: 30449536
Drug: Intramuscular methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular methylprednisolone acetate at 160 mg
Study: 25929594
Drug: Eltrombopag 25
Normalized name: eltrombopag 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 25 mg once daily
Study: 25526812
Drug: Multi-dimensional family
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dimensional family therapy (MDFT)
Study: 12566370
Drug: Enalaprilat (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (5 micro g/min)
Study: 12566370
Drug: Enalaprilat (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (5 micro g/min) with bradykinin (100 ng/min)
Study: 7972348
Drug: Propentofylline at
Normalized name: propentofylline
DrugBank: Propentofylline (DB06479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propentofylline at 0.9 g/d
Study: 2890150
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg at night)
Study: 2570005
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg at night)
Study: 16801
Drug: triazolam 0-5
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: triazolam 0-5 mg
Study: 16801
Drug: triazolam 0-25
Normalized name: triazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: triazolam 0-25 mg
Study: 19629539
Drug: Standard antiemetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiemetic treatment and standard care (Control group)
Study: 15142023
Drug: Creatine powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine powder in solution (CP) - 20 g.day(‐1) x 6 days
Study: 15142023
Drug: Creatine serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine serum (CS) - 5 ml.day(‐1) x 6 days
Study: 11701194
Drug: 4 standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 standard units of alcohol (40 g) under fasting conditions
Study: 11701194
Drug: 4 standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 standard units of alcohol (40 g) after food consumption
Study: 365544
Drug: Timolol and
Normalized name: timolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol and bendrofluazide (once daily dosage)
Study: 365544
Drug: Timolol and
Normalized name: timolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol and bendrofluazide (twice daily dosage)
Study: 28093841
Drug: Valsartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (160 mg daily)
Study: 23500262
Drug: Rivaroxaban (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (both doses)
Study: 19318434
Drug: Homozygous for
Normalized name: HOMOZYGOUS YUCATAN MINIATURE PIG ATAXIA TELANGIECTASIA MUTATED (ATM) GENE DISRUPTED BY A ATM-NEO RDNA CONSTRUCT IN EXON 57
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homozygous for the G allele of the PRKDC rs7003908 variant
Study: 8959084
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (20 mg) administered prior to and 16 hours after depot bromocriptine (50 or 100 mg) injection
Study: 8959084
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered prior to and 16 hours after depot bromocriptine (50 or 100 mg) injection
Study: 3893730
Drug: Naproxen (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (initial dose 750 mg, additional 250-500 mg as needed, max 5 tablets in 24h)
Study: 31610549
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg/d or 15 mg/d, according to renal function)
Study: 31610549
Drug: Dose‐adjusted vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose‐adjusted vitamin K antagonists (VKAs)
Study: 27321312
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + DPP4 inhibitors
Study: 27321312
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + insulin-secretagogues (IS)
Study: 22128201
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose, 75 mg/d for 4 days) with standard breakfast
Study: 22128201
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose, 75 mg/d for 4 days) in fasted state
Study: 12494713
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) using glass-ionomer (GI) and compomer materials
Study: 12494713
Drug: Minimal intervention
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal intervention treatment (MIT) using glass-ionomer (GI) and compomer materials
Study: 2533042
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg twice daily for 19 patients, 10 mg twice daily for 2 patients)
Study: 31813636
Drug: Accelerated Partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Partial Breast Irradiation (APBI) delivered as 34 Gy of brachytherapy or 38.5 Gy of external beam radiation therapy in 10 fractions over 5 treatment days within an 8-day period.
Study: 31813636
Drug: Whole-breast irradiation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-breast irradiation delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumour bed.
Study: 26185423
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) formulation of cilostazol 200 mg every 24 hours
Study: 26185423
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) formulation of cilostazol 100 mg every 12 hours
Study: 23448818
Drug: Delayed administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed administration of rabbit antithymocyte globulin
Study: 21063786
Drug: Acute migraine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute migraine treatment
Study: 26772449
Drug: Combined vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined vitamin A-zinc supplement
Study: 9306340
Drug: Intensified antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified antihypertensive treatment (felodipine, metoprolol, or ramipril)
Study: 8374373
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and non-steroidal anti-inflammatory drugs
Study: 8374373
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs prescribed for longer than five years
Study: 8374373
Drug: Paracetamol or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol or other drugs
Study: 26195963
Drug: Duloxetine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine therapy with pelvic floor exercise (Group A)
Study: 18307594
Drug: Lamivudine (LAM;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (LAM; 100 mg, q.d.)
Study: 18307594
Drug: Interferon +
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon + Lamivudine combination (2 months of LAM followed by combination treatment)
Study: 14762857
Drug: Interferon monotherapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon monotherapy
Study: 16451437
Drug: School-based caries
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based caries preventive program including intensive oral hygiene instructions and supervised daily tooth brushing with fluoridated toothpaste.
Study: 16451437
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only oral hygiene instructions sessions.
Study: 12954659
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in eugonadal men
Study: 6805647
Drug: Adrenergic-blocking agents
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic-blocking agents (propranolol and phentolamine or propranolol alone) for three weeks
Study: 30924762
Drug: Bridging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy (EVT with IVT)
Study: 11940752
Drug: Colforsin daropate
Normalized name: Tropine tropate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colforsin daropate (0.75 microg x kg(‐1) x min(‐1) continuous infusion for 60 min)
Study: 11940752
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (7.5 mL/hr continuous infusion)